• Publications
  • Influence
Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression
The present study investigated body weight gain, food intake, open-field activity and brain histamine H1 receptor mRNA and protein expression in rats treated with three types of antipsychotics. RatsExpand
Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia
Blockade of N-methyl-D-aspartate receptors (NMDARs) produces behavior in healthy people that is similar to the psychotic symptoms and cognitive deficits of schizophrenia and can exacerbate symptomsExpand
Short and long term changes in NMDA receptor binding in mouse brain following chronic phencyclidine treatment
SummaryPhencyclidine (PCP) is an antagonist of the NMDA subtype of glutamate receptor. PCP treatment induces psychosis in normal humans, which provides a valuable model of schizophrenia. PCPExpand
Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia
The posterior cingulate cortex (PCC) has recently been implicated in the pathophysiology of schizophrenia, through both animal and human studies. We have recently shown abnormal glutamate, GABA, andExpand
Negativity towards negative results: a discussion of the disconnect between scientific worth and scientific culture
ABSTRACT Science is often romanticised as a flawless system of knowledge building, where scientists work together to systematically find answers. In reality, this is not always the case.Expand
Ionotropic glutamate receptor binding in the posterior cingulate cortex in schizophrenia patients
Using quantitative autoradiography, the present study examined ionotropic glutamatergic receptor binding sites using [3H]dizocilpine, [3H]&agr;-amino-3-hydroxy-5-methylisoxazole-4-propionate, andExpand
Molecular evidence of synaptic pathology in the CA1 region in schizophrenia
Alterations of postsynaptic density (PSD)95-complex proteins in schizophrenia ostensibly induce deficits in synaptic plasticity, the molecular process underlying cognitive functions. Although someExpand
Rethinking metabotropic glutamate receptor 5 pathological findings in psychiatric disorders: implications for the future of novel therapeutics
BackgroundPharmacological modulation of metabotropic glutamate receptor 5 (mGluR5) is of marked interest as a novel therapeutic mechanism to treat schizophrenia and major depression. However, theExpand
Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia
The posterior cingulate cortex (PCC), a key component of the limbic system, has been implicated in the pathology of schizophrenia because of its sensitivity to NMDA receptor antagonists. RecentExpand
Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia
Metabotropic glutamate receptor 5 (mGluR5) potentiates the NMDA receptor (NMDAR) in brain regions implicated in schizophrenia, making it a viable therapeutic target for the treatment of thisExpand